Infections aspergillaires broncho-pulmonaires du sujet non immunodéprimé

Camuset, Juliette; Lavolé, A.; Wislez, Marie; Khalil, Antoine; Bellocq, A.; Bazelly, B; Mayaud, C; Cadranel, Jacques

doi:10.1016/s0761-8417(07)90120-0

Cited by 21 publications

(17 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hemoptysis remains the hallmark of pulmonary aspergilloma and is reported in 50 to 95% of cases, according to the authors [8,9,14,15,20,21]. This is what was observed in our series where 90% of our patients consulted for hemoptysis.…”

Section: Discussionsupporting

confidence: 83%

“…Aspergillus fumigatus is the species most often implicated in human disease, in temperate countries. It is responsible for 80 to 90% of pulmonary aspergillosis cases [1,2,9,10].…”

Section: Discussionmentioning

confidence: 99%

“…Histologically, the aspergilloma is a saprophytic proliferation of aspergillus spores organized as in a dense mycelial felting, or "mycetoma" within a preformed cavity [9,11,12] that is often a sequel of tuberculosis [3,8,[13][14][15].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Chronic pulmonary aspergillosis: A frequent and potentially severe disease

Benjelloun¹,

Zaghba²,

Yassine³

et al. 2015

Médecine et Maladies Infectieuses

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

“…Aspergillus fumigatus is the species most often implicated in human disease, in temperate countries. It is responsible for 80 to 90% of pulmonary aspergillosis cases [1,2,9,10].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic pulmonary aspergillosis: A frequent and potentially severe disease

Benjelloun¹,

Zaghba²,

Yassine³

et al. 2015

Médecine et Maladies Infectieuses

View full text Add to dashboard Cite

“…Some cases of SAIA have responded to long-term oral itraconazole in some cohort studies [31,86,87,93,94]. A prospective multicentre study of CPA patients treated with voriconazole confirmed data obtained in a preliminary study showing that voriconazole efficacy was significantly greater in patients with SAIA than in those with CCPA [15,90,95].…”

Section: Treatment and Follow-upmentioning

confidence: 74%

Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

Denning¹,

Cadranel²,

et al. 2015

View full text Add to dashboard Cite

Chronic pulmonary aspergillosis (CPA) is an uncommon and problematic pulmonary disease, complicating many other respiratory disorders, thought to affect ∼240 000 people in Europe. The most common form of CPA is chronic cavitary pulmonary aspergillosis (CCPA), which untreated may progress to chronic fibrosing pulmonary aspergillosis. Less common manifestations include: Aspergillus nodule and single aspergilloma. All these entities are found in non-immunocompromised patients with prior or current lung disease. Subacute invasive pulmonary aspergillosis (formerly called chronic necrotising pulmonary aspergillosis) is a more rapidly progressive infection (<3 months) usually found in moderately immunocompromised patients, which should be managed as invasive aspergillosis. Few clinical guidelines have been previously proposed for either diagnosis or management of CPA. A group of experts convened to develop clinical, radiological and microbiological guidelines. The diagnosis of CPA requires a combination of characteristics: one or more cavities with or without a fungal ball present or nodules on thoracic imaging, direct evidence of Aspergillus infection (microscopy or culture from biopsy) or an immunological response to Aspergillus spp. and exclusion of alternative diagnoses, all present for at least 3 months. Aspergillus antibody (precipitins) is elevated in over 90% of patients. Surgical excision of simple aspergilloma is recommended, if technically possible, and preferably via video-assisted thoracic surgery technique. Long-term oral antifungal therapy is recommended for CCPA to improve overall health status and respiratory symptoms, arrest haemoptysis and prevent progression. Careful monitoring of azole serum concentrations, drug interactions and possible toxicities is recommended. Haemoptysis may be controlled with tranexamic acid and bronchial artery embolisation, rarely surgical resection, and may be a sign of therapeutic failure and/or antifungal resistance. Patients with single Aspergillus nodules only need antifungal therapy if not fully resected, but if multiple they may benefit from antifungal treatment, and require careful follow-up. @ERSpublications ERS and ESCMID guideline for the management of chronic pulmonary aspergillosis released

show abstract

“…В проспективном многоцентровом исследова нии ХЛА с терапией вориконазолом подтвержде ны результаты предыдущего исследования, по ре зультатам которого показано, что эффективность вориконазола значительно выше при ПИА, чем при ХКЛА [15,90,95].…”

Section: лечение и наблюдениеunclassified

Diagnosis and treatment of chronic pulmonary aspergillosis: clinical guidelines of European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society

Denning¹,

Cadranel²,

Ader³

et al. 2017

Pulʹmonologiâ (Mosk.)

Self Cite

View full text Add to dashboard Cite

Chronic pulmonary aspergillosis (CPA) is infrequent respiratory disease which is difficult for diagnosis and can complicate other respiratory diseases and conditions. Currently, there are about 240,000 CPA patients in Europe. The most prevalent variant of CPA is chronic cavitary pulmonary aspergillosis (CCPA) which could progress to chronic fibrosing pulmonary aspergillosis (CFPA) when is untreated. Aspergillus nodules and single aspergilloma are less frequent clinical variants of this disease. All clinical variants of aspergillosis could be found in nonimmunocompromised patients with different underlying pulmonary disorders. Subacute invasive pulmonary aspergillosis, which was referred to as chronic necrotising pulmonary aspergillosis, is the most rapidly progressive clinical variant of the infection (< 3 months); it is typically diagnosed in moderately immunocompromised patients and should be treated as invasive aspergillosis. Diagnosis and management of CPA patients were previously described in sporadic guidelines. Due to this, expert group have been convened to develop clinical, radiological and microbiological guidelines. Diagnosis of CPA requires a combination of the following criteria existing for 3 months or more: one or more cavities in the lungs with or without fungal mass inside or nodules found on radiological examination; direct evidence of Aspergillus infection (using microscopic examination or biopsy culturing) or immunological response to Aspergillus spp. and exclusion of alternative diseases. Antibodies against Aspergillus spp. (precipitins) are increased in > 90% of patients. Aspergilloma should be resected if technically possible; videoassisted thoracic surgery is preferable. Chronic cavitary pulmonary aspergillosis requires longterm oral antifungal therapy to improve the patients' health and respiratory symptoms, to arrest haemoptysis and prevent the disease progression. Azole serum concentration and drug interaction should be thoroughly monitored to avoid toxic effects. Haemoptysis could be arrested using therapy with tranexamic acid or bronchial artery embolization; surgical resection of the lung is rarely required. Haemoptysis could indicate therapeutic failure and / or resistance to antifungals. Patients with a single Aspergillus nodule need antifungal therapy only if surgical resection is impossible. Antifungal therapy could be beneficial in patients with multiple Aspergillusis nodules; these patients need careful followup.

show abstract

Infections aspergillaires broncho-pulmonaires du sujet non immunodéprimé

Cited by 21 publications

References 50 publications

Chronic pulmonary aspergillosis: A frequent and potentially severe disease

Chronic pulmonary aspergillosis: A frequent and potentially severe disease

Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

Diagnosis and treatment of chronic pulmonary aspergillosis: clinical guidelines of European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society

Contact Info

Product

Resources

About